ClinicalTrials.gg
Status unknownNCT03374007GB226Updated Aug 16, 2021

Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma

A Phase 1 interventional study of Geptanolimab Injection 1mg/kg and Geptanolimab Injection 3mg/kg in Advanced Solid Tumor, Recurrent Solid Tumor and Lymphoma, sponsored by Genor Biopharma Co., Ltd.. Status unknown at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-08-16.

Primary conditionHodgkin DiseaseRegistry: LymphomaReclassifiedWhy we changed it
Registry
Lymphoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hodgkin Disease
Why
  1. The study's listed conditions name Hodgkin Disease, a narrower term within Lymphoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Genor Biopharma Co., Ltd. (part of Edding Genor Group Holdings Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

With open, single/ multiple dosing and dose escalation, phase I clinical trial scheme to evaluate safety, tolerance and pharmacokinetic properties of Genolimzumab injection in Chinese patients of advanced and (or) recurrent solid tumor/lymphoma

Read the detailed description

Recombinant Programmed death-1(PD-1) humanized monoclonal antibody injection (company code: GB226) is joint developed by Genor Biopharma Co. Ltd and Crown Bioscience,Inc., it is the reorganization of deoxyribonucleic acid (DNA) technology in the Chinese hamster ovary (CHO) cells express system expressed in a immunoglobulin G4 (IgG4) kappa type single resistance to predominate. GB226 had the different new amino acid sequence and molecular structure compared with two marketed PD-1 monoclonal antibody injection and got the approval of China Food and Drug Administration (CFDA) for clinical trial.Pharmaceutical research indicated GB226 cell strain had security source, production process is stable, quality can control, preparation stability, has good compatibility with packaging materials, it has the condition of industrialization, can prepare investigational medicinal product with safety, effective, and controlled quality for clinical research.Pharmacodynamics study show the targets and mechanisms of GB226 is clear, tumor suppression effect is obvious.Toxicology studies show this product in high doses with low toxic, and the toxic is reversible, the most common toxicity is specific to the drug action mechanism.

02

Conditions studied

  • Advanced Solid Tumor
  • Recurrent Solid Tumor
  • Lymphoma
  • Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma

Browse trials for

03

In context

Hodgkin Disease Reclassified

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

This study's planned enrollment of 72 is above the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.

Browse Hodgkin Disease studies →

Lead sponsor

Genor Biopharma Co., Ltd. is the lead sponsor of 24 studies on the registry; 4 are open to participants now.

First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited.

Compared within Hodgkin Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Age: 18-65. Unisex.
    1. Understand trial procedure and content and sign voluntarily;
    1. Patients of advanced (phase Ⅲb, multidisciplinary treatment is not appropriate), (phase IV) or recurrent solid tumor (including melanoma, NSCLC, renal cell carcinoma, head \& neck cancer, esophagus cancer, liver cancer, bladder cancer, spongioblastoma) or lymphoma (classical hodgkin lymphoma and (or) peripheral T-cell lymphoma, natural killer (NK)-T cell lymphoma and mediastinal B cell lymphoma) conformed by histology or cytology and cannot be cured by surgery. There is no effective standard treatment now.
    1. Agree to provide recorded tumor tissue sample or fresh tissue sample.
    1. (ECOG): 0-1;
    1. Expected life ≥ 3 months;
    1. With at least one measurable and evaluable tumor (solid tumor is subject to criteria for evaluating efficacy of Immune-Related Response Criteria (irRC)/ and lymphoma is subject to criteria/revised criteria of international working group);
    1. Chemotherapy of the whole body is completed at least 4 weeks before inclusion.
    1. Radiotherapy of the whole body and partial palliative radiotherapy are completed at least 4 weeks before inclusion.
    1. (prednisone>10mg/d or equivalent) has been stopped at least 2 weeks before inclusion.
    1. Autotransplantation is completed at least 3 months before inclusion.
    1. Major surgeries with the need of general anesthesia are completed at least 4 weeks. Surgeries with the need of local anesthesia/epidural anesthesia are completed at least 2 weeks and the subjects have recovered. Skin with the need of local anesthesia are completed at least 1 hour before inclusion.
    1. Previous tumor biotherapy (tumor vaccine, cell factor or growth factor for the purpose of tumor control) is completed at least 4 weeks before inclusion;
    1. Without severe haematological, cardiopulmonary, liver and kidney diseases except protopathic. For patients of solid tumor, ≥9g/dl, neutrophile granulocyte≥1.5×109/L, blood ≥100×1012/L. For patients of hematologic tumor, hemoglobin≥8g/dl, neutrophile granulocyte≥1.0×109/L, blood platelet≥80×1012/L.
    1. Serum creatinine≤1.5xUpper Limit Of Normal () or rate≥50mL/min and urine protein\<2+ in test paper of urine. For patients with urine protein great than or equal to 2+ in test paper of urine, urine shall be collected in 24 hours and urine protein must less than or be equal to 1g.

etc.

Exclusion criteria

Exclusion Criteria:

    1. Active central nervous system ; If central nervous system (CNS) metastasis of patients can be treated and their symptoms of nervous system can recover to the baseline level (excluding residual signs or symptoms related to CNS treatment) for 2 weeks when they are included, they can participate in the research. Cranial CT or MRI scanning shall be made for the patients 30 days before inclusion.
    1. Meningeal metastases or meningeal infiltration of tumors;
    1. Patients with other malignant tumors (excluding cured cervical carcinoma in situ and skin basal cell carcinoma) shall not participate in the research, unless he/she has been fully relieved at least 2 years without the need of other treatment or other treatment is not needed during the research.
    1. With active, known or suspected disease.
    1. With previous usage of antibody, PD-L1 antibody, PD-L2 antibody or cytotoxic T-lymphocyte-associated antigen-4 immunoglobulin (CTLA-4) antibody for treatment (or other antibody for co-stimulation or check point assess of T cells)
  • 6.With severe internal medicine diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled high blood pressure, active peptic ulcer, active bleeding.
    1. With active infection.
    1. With active tuberculosis infection; with active tuberculosis infection in the past.
    1. Positive surface antigen (HBsAg), antibody (HCV-Ab), acquired immunodeficiency syndrome antibody (Anti-) and treponema pallidum antibody (TP-Ab). Positive subjects of HBsAg may not be excluded from patients of liver cancer.
    1. Complication with the need of drug or complication with the need of for whole or partial body in the dosage of immunosuppressive action.

etc.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    GB226 1mg/kg single-dose

    Geptanolimab, 1mg/kg, i.v., single-dose

    Biological: Geptanolimab Injection 1mg/kg

  • Experimental
    GB226 3 mg/kg single-dose

    Geptanolimab, 3mg/kg, i.v., single-dose

    Biological: Geptanolimab Injection 3mg/kg

  • Experimental
    GB226 10mg/kg single-dose

    Geptanolimab 10mg/kg, i.v., single-dose

    Biological: Geptanolimab Injection 10mg/kg

  • Experimental
    GB226 1mg/kg multiple dosing, every 2 weeks

    Geptanolimab, 1mg/kg, i.v., q2w\*6

    Biological: Geptanolimab Injection 1mg/kg, q2w*6

  • Experimental
    GB226 3mg/kg multiple dosing,every 2 weeks

    Geptanolimab, 3mg/kg, i.v., q2w\*6

    Biological: Geptanolimab Injection 3mg/kg, q2w*6

  • Experimental
    GB226 10mg/kg multiple dosing, every 2 weeks

    Geptanolimab,10mg/kg, i.v., q2w\*6

    Biological: Geptanolimab Injection 10mg/kg, , q2w*6

  • Experimental
    GB226 280mg multiple dosing

    Geptanolimab, 280mg, i.v., q3w

    Biological: Geptanolimab Injection 280mg, q3w

  • Experimental
    GB226 3mg/kg multiple dosing

    Geptanolimab, 3mg/kg, i.v., q2w

    Biological: Geptanolimab Injection 3mg/kg, q2w

Interventions

  • BiologicalGeptanolimab Injection 1mg/kg

    Drug page: Geptanolimab

    single-dose:1mg/kg

    Also known as: Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection

  • BiologicalGeptanolimab Injection 3mg/kg

    Drug page: Geptanolimab

    single-dose: 3mg/kg

    Also known as: Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection

  • BiologicalGeptanolimab Injection 10mg/kg

    Drug page: Geptanolimab

    single-dose:10mg/kg

    Also known as: Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection

  • BiologicalGeptanolimab Injection 1mg/kg, q2w*6

    Drug page: Geptanolimab

    multiple dosing: 1mg/kg, q2w\*6

    Also known as: Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection

  • BiologicalGeptanolimab Injection 3mg/kg, q2w*6

    Drug page: Geptanolimab

    multiple dosing: 3mg/kg, q2w\*6

    Also known as: Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection

  • BiologicalGeptanolimab Injection 10mg/kg, , q2w*6

    Drug page: Geptanolimab

    multiple dosing: 10mg/kg, , q2w\*6

    Also known as: Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection

  • multiple dosing: 280mg, q3w

    Also known as: Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection

  • BiologicalGeptanolimab Injection 3mg/kg, q2w

    Drug page: Geptanolimab

    multiple dosing: 3mg/kg, q2w

    Also known as: Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection

06

What researchers measure

Primary outcomes

  1. adverse event

    adverse event

    Time frame: all adverse events will be recorded from the time the consent form is signed through 30 days following cessation of treatment.

  2. Serious Adverse Event

    Serious Adverse Event

    Time frame: all serious adverse events will be recorded from the time the consent form is signed through 30 days following cessation of treatment.

  3. Dose limiting Toxicity, DLT

    Dose limiting Toxicity, DLT

    Time frame: Day 1 to Day 28 after first dose

  4. Maximum Tolerated Dose, MTD

    Maximum Tolerated Dose, MTD

    Time frame: Day 1 to Day 28 after first dose

Secondary outcomes

  1. AUC 0-t

    AUC 0-t

    Time frame: up to 12 weeks

  2. C max

    C max

    Time frame: up to 12 weeks

  3. AUC 0-∞

    AUC 0-∞

    Time frame: up to 12 weeks

  4. T max

    T max

    Time frame: up to 12 weeks

  5. Vd

    Vd

    Time frame: up to 12 weeks

  6. Ke

    Ke

    Time frame: up to 12 weeks

  7. t 1/2

    t 1/2

    Time frame: up to 12 weeks

  8. CL

    CL

    Time frame: up to 12 weeks

  9. Anti-drug antibody, ADA

    Anti-drug antibody, ADA

    Time frame: up to 12 weeks

  10. IFN-γ concentration

    IFN-γ concentration

    Time frame: up to 12 weeks

  11. peripheral blood CD8+PD-1 receptor occupying ratio

    peripheral blood CD8+PD-1 receptor occupying ratio

    Time frame: up to 12 weeks

07

Study locations

1 of 2 sites recruiting
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
    Not yet recruiting
    • Yuankai Shi, Doctor · Contact
    • Yuankai Shi, Doctor · Principal investigator
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
    Recruiting
    • Qingyuan Zhang, Doctor · Contact
    • Qingyuan Zhang, Doctor · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — There is not a plan to make individual participant data available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2017 (actual). Primary completion is estimated for Jun 2022, 56 months after the start.

Of 91 phase 1 interventional studies under Hodgkin Disease, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 79. This study's planned 56 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2017
First posted
Dec 14, 2017
StartActual
Oct 19, 2017
Primary completionEst.
Jun 2022
CompletionEst.
Aug 2022
Last update
Aug 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03374007
Responsible party
Sponsor
First posted
Dec 14, 2017
Start date
Oct 19, 2017
Primary completion
Jun 2022 (estimated)
Completion
Aug 2022 (estimated)
Last update
Aug 16, 2021

Study contacts

Shawn Yu, Master
Contact
shawn.yu@genorbio.com
86-010-65260820
Yuankai Shi, Doctor
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Geptanolimab

Start the discussion